. Author manuscript; available in PMC: 2009 Jan 8.

Published in final edited form as: J Cardiovasc Electrophysiol. 2008 May 9;19(10):1090–1097. doi: 10.1111/j.1540-8167.2008.01200.x

TABLE 2.

Effects of Procainamide and Sotalol on Activation Patterns During VF in Procainamide-First Group (n = 6)

	Baseline	Procainamide	Baseline vs Procainamide %change	Combination Procainamide + Sotalol	Baseline vs Combination %change	Procainamide vs Combination %change
Number of wavefronts	71 ± 23	42 ± 10	41%↓^**	35 ± 11	51%↓^**	17%↓^‡
Area swept out (mm²)	228 ± 36	234 ± 49	3%↑	275 ± 71	21%↑^**	18%↑ ^‡
Fractionation incidence	0.11 ± 0.04	0.09 ± 0.06	18%↓^**	0.11 ± 0.06	→	18%↑ ^‡
Collision incidence	0.12 ± 0.05	0.10 ± 0.05	17%↓^**	0.11 ± 0.05	8%↓^**	10%↑
Block incidence	0.34 ± 0.08	0.37 ± 0.12	9%↑	0.35 ± 0.13	3%↑	3%↓
Breakthrough incidence	0.29 ± 0.07	0.30 ± 0.12	3%↑	0.27 ± 0.09	7%↓^*	10%↓ ^‡
Multiplicity	12.5 ± 4.2	6.9 ± 2.1	45%↓^**	6.0 ± 2.1	52%↓^**	13%↓ ^‡
Repeatability	5.5 ± 10.	5.8 ± 1.0	5%↑^*	6.0 ± 1.7	9%↑^**	3%↑
Activation rate (s⁻¹)	9.4 ± 1.4	6.8 ± 1.1	28%↓^**	6.7 ± 1.0	29%↓^**	1%↓
Velocity (m/s)	0.46 ± 0.07	0.38 ± 0.05	17%↓^**	0.39 ± 0.05	15%↓^**	3%↑
Peak-dV/dt (V/s)	−1.0 ± 0.09	−0.97 ± 0.06	3%↓^**	−0.99 ± 0.14	1%↓^**	2%↑
Reentry incidence	1.2 ± 1.1	1.0 ± 1.5	17%↓	0.3 ± 0.5	75%↓^**	70%↓ ^‡

P < 0.05,

^**

P < 0.01 compared to baseline,

^†

P < 0.05,

^‡

P < 0.01 compared to monotherapy.